Analysts Set American Renal Associates Holdings Inc (NYSE:ARA) Price Target at $10.33

American Renal Associates Holdings Inc (NYSE:ARA) has been given an average rating of “Hold” by the eight analysts that are presently covering the stock, Marketbeat reports. Seven investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $10.33.

Several research firms have commented on ARA. SunTrust Banks upped their price objective on shares of American Renal Associates from $7.00 to $12.00 and gave the company a “hold” rating in a report on Tuesday, September 10th. ValuEngine raised shares of American Renal Associates from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cubist Systematic Strategies LLC bought a new stake in shares of American Renal Associates during the second quarter valued at about $233,000. Marshall Wace LLP increased its position in shares of American Renal Associates by 715.2% during the second quarter. Marshall Wace LLP now owns 92,039 shares of the company’s stock valued at $684,000 after buying an additional 80,748 shares during the period. Morgan Stanley increased its position in shares of American Renal Associates by 68.5% during the second quarter. Morgan Stanley now owns 5,932 shares of the company’s stock valued at $44,000 after buying an additional 2,412 shares during the period. A.R.T. Advisors LLC bought a new stake in shares of American Renal Associates during the second quarter valued at about $146,000. Finally, BlackRock Inc. increased its position in shares of American Renal Associates by 28.7% during the second quarter. BlackRock Inc. now owns 1,196,668 shares of the company’s stock valued at $8,904,000 after buying an additional 266,776 shares during the period. Hedge funds and other institutional investors own 86.23% of the company’s stock.

NYSE ARA traded down $0.06 during trading on Friday, hitting $6.73. 132,177 shares of the company’s stock traded hands, compared to its average volume of 232,657. The stock has a market capitalization of $221.11 million, a price-to-earnings ratio of 9.99 and a beta of 2.01. American Renal Associates has a 12-month low of $5.48 and a 12-month high of $20.97. The company has a debt-to-equity ratio of 7.82, a quick ratio of 1.00 and a current ratio of 1.03. The business has a 50 day moving average of $7.29 and a 200-day moving average of $6.91.

About American Renal Associates

American Renal Associates Holdings, Inc operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease.

Featured Story: Cost of Equity For A Business, Investors

Analyst Recommendations for American Renal Associates (NYSE:ARA)

Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.